Skip to main content
Erschienen in: Clinical & Experimental Metastasis 4/2008

01.06.2008 | Review

Extravasation and homing mechanisms in multiple myeloma

verfasst von: Isabelle Vande Broek, Karin Vanderkerken, Benjamin Van Camp, Ivan Van Riet

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Multiple myeloma (MM) is a malignant B-cell disorder characterized by a monoclonal expansion of plasma cells (PC) in the bone marrow (BM). During the main course of disease evolution, MM cells depend on the BM microenvironment for their growth and survival. Reciprocal interactions between MM cells and the BM mediate not only MM cell growth, but also protect them against apoptosis and cause bone disease and angiogenesis. A striking feature of MM represents the predominant localization and retention of MM cells in the BM. Although BM PC indeed represent the main neoplastic cell type, small numbers of MM cells can also be detected in the peripheral blood circulation. It can be assumed that these circulating cells represent the tumour-spreading component of the disease. This implicates that MM cells have the capacity to (re)circulate, to extravasate and to migrate to the BM (homing). In analogy to the migration and homing of normal leucocytes, the BM homing of MM cells is mediated by a multistep process of extravasation with adhesion to the endothelium, invasion of the subendothelial basement membrane, followed by further migration within the stroma, mediated by chemotactic factors. At the end stage of disease, MM cells are thought to develop autocrine growth supporting loops that enable them to survive and proliferate in the absence of the BM microenvironment and to become stroma-independent. In this stage, the number of circulating cells increases and growth at extramedullary sites can occur, associated with alteration in adhesion molecule and chemokine receptor expression. This review summarizes the recent progress in the study of the extravasation and homing mechanisms of MM cells.
Literatur
2.
Zurück zum Zitat Bakkus MH, Heirman C, Van Riet I, Van Camp B, Thielemans K (1992) Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 80(9):2326–2335PubMed Bakkus MH, Heirman C, Van Riet I, Van Camp B, Thielemans K (1992) Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 80(9):2326–2335PubMed
3.
Zurück zum Zitat Yaccoby S, Barlogie B, Epstein J (1998) Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 92(8):2908–2913PubMed Yaccoby S, Barlogie B, Epstein J (1998) Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 92(8):2908–2913PubMed
4.
Zurück zum Zitat Yaccoby S, Epstein J (1999) The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 94(10):3576–3582PubMed Yaccoby S, Epstein J (1999) The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 94(10):3576–3582PubMed
5.
Zurück zum Zitat Yata K, Yaccoby S (2004) The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 18(11):1891–1897PubMedCrossRef Yata K, Yaccoby S (2004) The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 18(11):1891–1897PubMedCrossRef
6.
Zurück zum Zitat Witzig TE, Kimlinger TK, Ahmann GJ, Katzmann JA, Greipp PR (1996) Detection of myeloma cells in the peripheral blood by flow cytometry. Cytometry 26(2):113–120PubMedCrossRef Witzig TE, Kimlinger TK, Ahmann GJ, Katzmann JA, Greipp PR (1996) Detection of myeloma cells in the peripheral blood by flow cytometry. Cytometry 26(2):113–120PubMedCrossRef
7.
Zurück zum Zitat Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC (2006) The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 42(11):1564–1573PubMedCrossRef Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC (2006) The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 42(11):1564–1573PubMedCrossRef
8.
Zurück zum Zitat Hallek M, Bergsagel PL, Anderson KC (1998) Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91(1):3–21PubMed Hallek M, Bergsagel PL, Anderson KC (1998) Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91(1):3–21PubMed
9.
Zurück zum Zitat Hideshima T, Nakamura N, Chauhan D, Anderson KC (2001) Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 20(42):5991–6000PubMedCrossRef Hideshima T, Nakamura N, Chauhan D, Anderson KC (2001) Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 20(42):5991–6000PubMedCrossRef
10.
Zurück zum Zitat Qiang YW, Kopantzev E, Rudikoff S (2002) Insulin-like growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 99(11):4138–4146PubMedCrossRef Qiang YW, Kopantzev E, Rudikoff S (2002) Insulin-like growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 99(11):4138–4146PubMedCrossRef
11.
Zurück zum Zitat Podar K, Anderson KC (2005) The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 105(4):1383–1395PubMedCrossRef Podar K, Anderson KC (2005) The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 105(4):1383–1395PubMedCrossRef
12.
Zurück zum Zitat Bataille R, Chappard D, Marcelli C, Dessauw P, Sany J, Baldet P, Alexandre C (1989) Mechanisms of bone destruction in multiple myeloma: the importance of anunbalanced process in determining the severity of lytic bone disease. J Clin Oncol 7(12):1909–1914PubMed Bataille R, Chappard D, Marcelli C, Dessauw P, Sany J, Baldet P, Alexandre C (1989) Mechanisms of bone destruction in multiple myeloma: the importance of anunbalanced process in determining the severity of lytic bone disease. J Clin Oncol 7(12):1909–1914PubMed
13.
Zurück zum Zitat Roux S, Meignin V, Quillard J, Meduri G, Guiochon-Mantel A, Fermand JP, Milgrom E, Mariette X (2002) RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol 117(1):86–92PubMedCrossRef Roux S, Meignin V, Quillard J, Meduri G, Guiochon-Mantel A, Fermand JP, Milgrom E, Mariette X (2002) RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol 117(1):86–92PubMedCrossRef
14.
Zurück zum Zitat Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y (2001) Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98(20):11581–11586PubMedCrossRef Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y (2001) Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98(20):11581–11586PubMedCrossRef
15.
Zurück zum Zitat Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S (2001) Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98(13):3527–3533PubMedCrossRef Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S (2001) Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98(13):3527–3533PubMedCrossRef
16.
Zurück zum Zitat Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD, Alsina M (2000) Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96(2):671–675PubMed Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD, Alsina M (2000) Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96(2):671–675PubMed
17.
Zurück zum Zitat Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D, Matsumoto T (2002) Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100(6):2195–2202PubMed Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D, Matsumoto T (2002) Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100(6):2195–2202PubMed
18.
Zurück zum Zitat Oba Y, Lee JW, Ehrlich LA, Chung HY, Jelinek DF, Callander NS, Horuk R, Choi SJ, Roodman GD (2005) MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol 33(3):272–278PubMedCrossRef Oba Y, Lee JW, Ehrlich LA, Chung HY, Jelinek DF, Callander NS, Horuk R, Choi SJ, Roodman GD (2005) MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol 33(3):272–278PubMedCrossRef
19.
Zurück zum Zitat Zannettino AC, Farrugia AN, Kortesidis A, Manavis J, To LB, Martin SK, Diamond P, Tamamura H, Lapidot T, Fujii N, Gronthos S (2005) Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 65(5):1700–1709PubMedCrossRef Zannettino AC, Farrugia AN, Kortesidis A, Manavis J, To LB, Martin SK, Diamond P, Tamamura H, Lapidot T, Fujii N, Gronthos S (2005) Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 65(5):1700–1709PubMedCrossRef
20.
Zurück zum Zitat Michigami T, Shimizu N, Williams PJ, Niewolna M, Dallas SL, Mundy GR, Yoneda T (2000) Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 96(5):1953–1960PubMed Michigami T, Shimizu N, Williams PJ, Niewolna M, Dallas SL, Mundy GR, Yoneda T (2000) Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 96(5):1953–1960PubMed
21.
Zurück zum Zitat Cozzolino F, Torcia M, Aldinucci D, Rubartelli A, Miliani A, Shaw AR, Lansdorp PM, Di Guglielmo R (1989) Production of interleukin-1 by bone marrow myeloma cells. Blood 74(1):380–387PubMed Cozzolino F, Torcia M, Aldinucci D, Rubartelli A, Miliani A, Shaw AR, Lansdorp PM, Di Guglielmo R (1989) Production of interleukin-1 by bone marrow myeloma cells. Blood 74(1):380–387PubMed
22.
Zurück zum Zitat Barille S, Bataille R, Amiot M (2000) The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma. Eur Cytokine Netw 11(4):546–551PubMed Barille S, Bataille R, Amiot M (2000) The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma. Eur Cytokine Netw 11(4):546–551PubMed
23.
Zurück zum Zitat Garrett IR, Durie BG, Nedwin GE, Gillespie A, Bringman T, Sabatini M, Bertolini DR, Mundy GR (1987) Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med 317(9):526–533PubMedCrossRef Garrett IR, Durie BG, Nedwin GE, Gillespie A, Bringman T, Sabatini M, Bertolini DR, Mundy GR (1987) Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med 317(9):526–533PubMedCrossRef
24.
Zurück zum Zitat Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD, Choi SJ (2004) IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 103(6):2308–2315PubMedCrossRef Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD, Choi SJ (2004) IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 103(6):2308–2315PubMedCrossRef
25.
Zurück zum Zitat Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349(26):2483–2494PubMedCrossRef Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349(26):2483–2494PubMedCrossRef
26.
Zurück zum Zitat Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, Grano M, Colucci S, Svaldi M, Rizzoli V (2005) Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106(7):2472–2483PubMedCrossRef Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, Grano M, Colucci S, Svaldi M, Rizzoli V (2005) Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106(7):2472–2483PubMedCrossRef
27.
Zurück zum Zitat Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T (2004) Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104(8):2484–2491PubMedCrossRef Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T (2004) Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104(8):2484–2491PubMedCrossRef
28.
Zurück zum Zitat Vacca A, Ribatti D (2006) Bone marrow angiogenesis in multiple myeloma. Leukemia 20(2):193–199PubMedCrossRef Vacca A, Ribatti D (2006) Bone marrow angiogenesis in multiple myeloma. Leukemia 20(2):193–199PubMedCrossRef
29.
Zurück zum Zitat Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ, Greipp PR (2002) Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 8(7):2210–2216PubMed Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ, Greipp PR (2002) Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 8(7):2210–2216PubMed
30.
Zurück zum Zitat Asosingh K, De Raeve H, Menu E, Van Riet I, Van Marck E, Van Camp B, Vanderkerken K (2004) Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity. Blood 103(8):3131–3137PubMedCrossRef Asosingh K, De Raeve H, Menu E, Van Riet I, Van Marck E, Van Camp B, Vanderkerken K (2004) Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity. Blood 103(8):3131–3137PubMedCrossRef
31.
Zurück zum Zitat Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, Dammacco F (1994) Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87(3):503–508PubMedCrossRef Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, Dammacco F (1994) Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87(3):503–508PubMedCrossRef
32.
Zurück zum Zitat Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Wellik LA, Fonseca R, Lust JA, Witzig TE, Kyle RA, Greipp PR, Rajkumar SV (2004) Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant 34(3):235–239PubMedCrossRef Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Wellik LA, Fonseca R, Lust JA, Witzig TE, Kyle RA, Greipp PR, Rajkumar SV (2004) Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant 34(3):235–239PubMedCrossRef
33.
Zurück zum Zitat Sezer O, Niemoller K, Eucker J, Jakob C, Kaufmann O, Zavrski I, Dietel M, Possinger K (2000) Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 79(10):574–577PubMedCrossRef Sezer O, Niemoller K, Eucker J, Jakob C, Kaufmann O, Zavrski I, Dietel M, Possinger K (2000) Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 79(10):574–577PubMedCrossRef
34.
Zurück zum Zitat Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR (2000) Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 6(8):3111–3116PubMed Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR (2000) Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 6(8):3111–3116PubMed
35.
Zurück zum Zitat Pruneri G, Ponzoni M, Ferreri AJ, Decarli N, Tresoldi M, Raggi F, Baldessari C, Freschi M, Baldini L, Goldaniga M, Neri A, Carboni N, Bertolini F, Viale G (2002) Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol 118(3):817–822PubMedCrossRef Pruneri G, Ponzoni M, Ferreri AJ, Decarli N, Tresoldi M, Raggi F, Baldessari C, Freschi M, Baldini L, Goldaniga M, Neri A, Carboni N, Bertolini F, Viale G (2002) Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol 118(3):817–822PubMedCrossRef
36.
Zurück zum Zitat Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P, Sortino G, Giustolisi R (2000) Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 85(8):800–805PubMed Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P, Sortino G, Giustolisi R (2000) Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 85(8):800–805PubMed
37.
Zurück zum Zitat Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM, Serve H, Berdel WE, Kienast J (2000) Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95(8):2630–2636PubMed Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM, Serve H, Berdel WE, Kienast J (2000) Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95(8):2630–2636PubMed
38.
Zurück zum Zitat Tai YT, Podar K, Mitsiades N, Lin B, Mitsiades C, Gupta D, Akiyama M, Catley L, Hideshima T, Munshi NC, Treon SP, Anderson KC (2003) CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood 101(7):2762–2769PubMedCrossRef Tai YT, Podar K, Mitsiades N, Lin B, Mitsiades C, Gupta D, Akiyama M, Catley L, Hideshima T, Munshi NC, Treon SP, Anderson KC (2003) CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood 101(7):2762–2769PubMedCrossRef
39.
Zurück zum Zitat Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, Lin BK, Gupta D, Shima Y, Chauhan D, Mitsiades C, Raje N, Richardson P, Anderson KC (2001) Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98:428–435PubMedCrossRef Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, Lin BK, Gupta D, Shima Y, Chauhan D, Mitsiades C, Raje N, Richardson P, Anderson KC (2001) Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98:428–435PubMedCrossRef
40.
Zurück zum Zitat Podar K, Tai YT, Lin BK, Narsimhan RP, Sattler M, Kijima T, Salgia R, Gupta D, Chauhan D, Anderson KC (2002) Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem 277(10):7875–7881PubMedCrossRef Podar K, Tai YT, Lin BK, Narsimhan RP, Sattler M, Kijima T, Salgia R, Gupta D, Chauhan D, Anderson KC (2002) Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem 277(10):7875–7881PubMedCrossRef
41.
Zurück zum Zitat Vacca A, Ria R, Ribatti D, Semeraro F, Djonov V, Di Raimondo F, Dammacco F (2003) A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 88(2):176–185PubMed Vacca A, Ria R, Ribatti D, Semeraro F, Djonov V, Di Raimondo F, Dammacco F (2003) A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 88(2):176–185PubMed
42.
Zurück zum Zitat Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI, Anderson KC (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15(12):1950–1961PubMed Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI, Anderson KC (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15(12):1950–1961PubMed
43.
Zurück zum Zitat Giuliani N, Lunghi P, Morandi F, Colla S, Bonomini S, Hojden M, Rizzoli V, Bonati A (2004) Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia 18(3):628–635PubMedCrossRef Giuliani N, Lunghi P, Morandi F, Colla S, Bonomini S, Hojden M, Rizzoli V, Bonati A (2004) Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia 18(3):628–635PubMedCrossRef
44.
Zurück zum Zitat Bisping G, Leo R, Wenning D, Dankbar B, Padro T, Kropff M, Scheffold C, Kroger M, Mesters RM, Berdel WE, Kienast J (2003) Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 101(7):2775–2783PubMedCrossRef Bisping G, Leo R, Wenning D, Dankbar B, Padro T, Kropff M, Scheffold C, Kroger M, Mesters RM, Berdel WE, Kienast J (2003) Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 101(7):2775–2783PubMedCrossRef
45.
Zurück zum Zitat Colla S, Morandi F, Lazzaretti M, Rizzato R, Lunghi P, Bonomini S, Mancini C, Pedrazzoni M, Crugnola M, Rizzoli V, Giuliani N (2005) Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia 19(12):2166–2176PubMedCrossRef Colla S, Morandi F, Lazzaretti M, Rizzato R, Lunghi P, Bonomini S, Mancini C, Pedrazzoni M, Crugnola M, Rizzoli V, Giuliani N (2005) Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia 19(12):2166–2176PubMedCrossRef
46.
Zurück zum Zitat Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C, Bonomini S, Lunghi P, Hojden M, Genestreti G, Svaldi M, Coser P, Fattori PP, Sammarelli G, Gazzola GC, Bataille R, Almici C, Caramatti C, Mangoni L, Rizzoli V (2003) Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 102(2):638–645PubMedCrossRef Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C, Bonomini S, Lunghi P, Hojden M, Genestreti G, Svaldi M, Coser P, Fattori PP, Sammarelli G, Gazzola GC, Bataille R, Almici C, Caramatti C, Mangoni L, Rizzoli V (2003) Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 102(2):638–645PubMedCrossRef
47.
Zurück zum Zitat Tanaka Y, Abe M, Hiasa M, Oda A, Amou H, Nakano A, Takeuchi K, Kitazoe K, Kido S, Inoue D, Moriyama K, Hashimoto T, Ozaki S, Matsumoto T (2007) Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 13(3):816–823PubMedCrossRef Tanaka Y, Abe M, Hiasa M, Oda A, Amou H, Nakano A, Takeuchi K, Kitazoe K, Kido S, Inoue D, Moriyama K, Hashimoto T, Ozaki S, Matsumoto T (2007) Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 13(3):816–823PubMedCrossRef
48.
Zurück zum Zitat Picker LJ, Butcher EC (1992) Physiological and molecular mechanisms of lymphocyte homing. Annu Rev Immunol 10:561–591PubMedCrossRef Picker LJ, Butcher EC (1992) Physiological and molecular mechanisms of lymphocyte homing. Annu Rev Immunol 10:561–591PubMedCrossRef
49.
50.
Zurück zum Zitat Vanderkerken K, De Greef C, Asosingh K, Arteta B, De Veerman M, Vande Broek I, Van Riet I, Kobayashi M, Smedsrod B, Van Camp B (2000) Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse. Br J Cancer 82(4):953–959PubMedCrossRef Vanderkerken K, De Greef C, Asosingh K, Arteta B, De Veerman M, Vande Broek I, Van Riet I, Kobayashi M, Smedsrod B, Van Camp B (2000) Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse. Br J Cancer 82(4):953–959PubMedCrossRef
51.
Zurück zum Zitat Alici E, Konstantinidis KV, Aints A, Dilber MS, Abedi-Valugerdi M (2004) Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma. Exp Hematol 32(11):1064–1072PubMedCrossRef Alici E, Konstantinidis KV, Aints A, Dilber MS, Abedi-Valugerdi M (2004) Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma. Exp Hematol 32(11):1064–1072PubMedCrossRef
52.
Zurück zum Zitat Van Riet I, Van Camp B (1993) The involvement of adhesion molecules in the biology of multiple myeloma. Leuk Lymphoma 9(6):441–452PubMedCrossRef Van Riet I, Van Camp B (1993) The involvement of adhesion molecules in the biology of multiple myeloma. Leuk Lymphoma 9(6):441–452PubMedCrossRef
53.
Zurück zum Zitat Van Riet I, Vanderkerken K, de Greef C, Van Camp B (1998) Homing behaviour of the malignant cell clone in multiple myeloma. Med Oncol 15:154–164PubMedCrossRef Van Riet I, Vanderkerken K, de Greef C, Van Camp B (1998) Homing behaviour of the malignant cell clone in multiple myeloma. Med Oncol 15:154–164PubMedCrossRef
54.
Zurück zum Zitat Asosingh K, De Raeve H, Croucher P, Goes E, Van Riet I, Van Camp B, Vanderkerken K (2001) In vivo homing and differentiation characteristics of mature (CD45−) and immature (CD45+) 5T multiple myeloma cells. Exp Hematol 29(1):77–86PubMedCrossRef Asosingh K, De Raeve H, Croucher P, Goes E, Van Riet I, Van Camp B, Vanderkerken K (2001) In vivo homing and differentiation characteristics of mature (CD45−) and immature (CD45+) 5T multiple myeloma cells. Exp Hematol 29(1):77–86PubMedCrossRef
55.
Zurück zum Zitat Sanz-Rodriguez F, Hidalgo A, Teixido J (2001) Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 97(2):346–351PubMedCrossRef Sanz-Rodriguez F, Hidalgo A, Teixido J (2001) Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 97(2):346–351PubMedCrossRef
56.
Zurück zum Zitat Okada T, Hawley RG, Kodaka M, Okuno H (1999) Significance of VLA-4-VCAM-1 interaction and CD44 for transendothelial invasion in a bone marrow metastatic myeloma model. Clin Exp Metastasis 17(7):623–629PubMedCrossRef Okada T, Hawley RG, Kodaka M, Okuno H (1999) Significance of VLA-4-VCAM-1 interaction and CD44 for transendothelial invasion in a bone marrow metastatic myeloma model. Clin Exp Metastasis 17(7):623–629PubMedCrossRef
57.
Zurück zum Zitat Klominek J, Robert KH, Sundqvist KG (1993) Chemotaxis and haptotaxis of human malignant mesothelioma cells: effects of fibronectin, laminin, type IV collagen, and an autocrine motility factor-like substance. Cancer Res 53(18):4376–4382PubMed Klominek J, Robert KH, Sundqvist KG (1993) Chemotaxis and haptotaxis of human malignant mesothelioma cells: effects of fibronectin, laminin, type IV collagen, and an autocrine motility factor-like substance. Cancer Res 53(18):4376–4382PubMed
58.
Zurück zum Zitat Engbring JA, Kleinman HK (2003) The basement membrane matrix in malignancy. J Pathol 200(4):465–470PubMedCrossRef Engbring JA, Kleinman HK (2003) The basement membrane matrix in malignancy. J Pathol 200(4):465–470PubMedCrossRef
59.
Zurück zum Zitat Vande Broek I, Vanderkerken K, De Greef C, Asosingh K, Straetmans N, Van Camp B, Van Riet I (2001) Laminin-1-induced migration of multiple myeloma cells involves the high-affinity 67 kD laminin receptor. Br J Cancer 85(9):1387–1395CrossRef Vande Broek I, Vanderkerken K, De Greef C, Asosingh K, Straetmans N, Van Camp B, Van Riet I (2001) Laminin-1-induced migration of multiple myeloma cells involves the high-affinity 67 kD laminin receptor. Br J Cancer 85(9):1387–1395CrossRef
60.
Zurück zum Zitat Malinoff HL, Wicha MS (1983) Isolation of a cell surface receptor protein for laminin from murine fibrosarcoma cells. J Cell Biol 96:1475–1479PubMedCrossRef Malinoff HL, Wicha MS (1983) Isolation of a cell surface receptor protein for laminin from murine fibrosarcoma cells. J Cell Biol 96:1475–1479PubMedCrossRef
61.
Zurück zum Zitat van den Brule FA, Price J, Sobel ME, Lambotte R, Castronovo V (1994) Inverse expression of two laminin binding proteins, 67LR and galectin-3, correlates with the invasive phenotype of trophoblastic tissue. Biochem Biophys Res Commun 201(1):388–393PubMedCrossRef van den Brule FA, Price J, Sobel ME, Lambotte R, Castronovo V (1994) Inverse expression of two laminin binding proteins, 67LR and galectin-3, correlates with the invasive phenotype of trophoblastic tissue. Biochem Biophys Res Commun 201(1):388–393PubMedCrossRef
62.
Zurück zum Zitat Menard S, Tagliabue E, Colnaghi MI (1998) The 67 kDa laminin receptor as a prognostic factor in human cancer. Breast Cancer Res Treat 52:137–145PubMedCrossRef Menard S, Tagliabue E, Colnaghi MI (1998) The 67 kDa laminin receptor as a prognostic factor in human cancer. Breast Cancer Res Treat 52:137–145PubMedCrossRef
63.
Zurück zum Zitat Boukerche H, Su ZZ, Kang DC, Fisher PB (2004) Identification and cloning of genes displaying elevated expression as a consequence of metastatic progression in human melanoma cells by rapid subtraction hybridization. Gene 343(1):191–201PubMedCrossRef Boukerche H, Su ZZ, Kang DC, Fisher PB (2004) Identification and cloning of genes displaying elevated expression as a consequence of metastatic progression in human melanoma cells by rapid subtraction hybridization. Gene 343(1):191–201PubMedCrossRef
64.
Zurück zum Zitat Selleri C, Ragno P, Ricci P, Visconte V, Scarpato N, Carriero MV, Rotoli B, Rossi G, Montuori N (2006) The metastasis-associated 67-kDa laminin receptor is involved in G-CSF-induced hematopoietic stem cell mobilization. Blood 108(7):2476–2484PubMedCrossRef Selleri C, Ragno P, Ricci P, Visconte V, Scarpato N, Carriero MV, Rotoli B, Rossi G, Montuori N (2006) The metastasis-associated 67-kDa laminin receptor is involved in G-CSF-induced hematopoietic stem cell mobilization. Blood 108(7):2476–2484PubMedCrossRef
65.
Zurück zum Zitat Graf J, Iwamoto Y, Sasaki M, Martin GR, Kleinman HK, Robey FA, Yamada Y (1987) Identification of an amino acid sequence in laminin mediating cell attachment, chemotaxis, and receptor binding. Cell 48:989–996PubMedCrossRef Graf J, Iwamoto Y, Sasaki M, Martin GR, Kleinman HK, Robey FA, Yamada Y (1987) Identification of an amino acid sequence in laminin mediating cell attachment, chemotaxis, and receptor binding. Cell 48:989–996PubMedCrossRef
66.
Zurück zum Zitat Vande Broek I, Asosingh K, Vanderkerken K, Straetmans N, Van Camp B, Van Riet I (2003) Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer 88(6):855–862CrossRef Vande Broek I, Asosingh K, Vanderkerken K, Straetmans N, Van Camp B, Van Riet I (2003) Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer 88(6):855–862CrossRef
67.
Zurück zum Zitat Moller C, Stromberg T, Juremalm M, Nilsson K, Nilsson G (2003) Expression and function of chemokine receptors in human multiple myeloma. Leukemia 17(1):203–210PubMedCrossRef Moller C, Stromberg T, Juremalm M, Nilsson K, Nilsson G (2003) Expression and function of chemokine receptors in human multiple myeloma. Leukemia 17(1):203–210PubMedCrossRef
68.
Zurück zum Zitat Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, Yoshie O (2003) Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol 170(3):1136–1140PubMed Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, Yoshie O (2003) Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol 170(3):1136–1140PubMed
69.
Zurück zum Zitat Pellegrino A, Antonaci F, Russo F, Merchionne F, Ribatti D, Vacca A, Dammacco F (2004) CXCR3-binding chemokines in multiple myeloma. Cancer Lett 207(2):221–227PubMedCrossRef Pellegrino A, Antonaci F, Russo F, Merchionne F, Ribatti D, Vacca A, Dammacco F (2004) CXCR3-binding chemokines in multiple myeloma. Cancer Lett 207(2):221–227PubMedCrossRef
70.
Zurück zum Zitat Menu E, Asosingh K, Indraccolo S, De Raeve H, Van Riet I, Van Valckenborgh E, Vande Broek I, Fujii N, Tamamura H, Van Camp B, Vanderkerken K (2006) The involvement of stromal derived factor 1 alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica 91(5):605–612PubMed Menu E, Asosingh K, Indraccolo S, De Raeve H, Van Riet I, Van Valckenborgh E, Vande Broek I, Fujii N, Tamamura H, Van Camp B, Vanderkerken K (2006) The involvement of stromal derived factor 1 alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica 91(5):605–612PubMed
71.
Zurück zum Zitat Menu E, De Leenheer E, De Raeve H, Coulton L, Imanishi T, Miyashita K, Van Valckenborgh E, Van Riet I, Van Camp B, Horuk R, Croucher P, Vanderkerken K (2006) Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis 23(5–6):291–300PubMedCrossRef Menu E, De Leenheer E, De Raeve H, Coulton L, Imanishi T, Miyashita K, Van Valckenborgh E, Van Riet I, Van Camp B, Horuk R, Croucher P, Vanderkerken K (2006) Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis 23(5–6):291–300PubMedCrossRef
72.
Zurück zum Zitat Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, Spencer JA, Kimlinger T, Ghobrial JM, Jia X, Lu G, Timm M, Kumar A, Cote D, Veilleux I, Hedin KE, Roodman GD, Witzig TE, Kung AL, Hideshima T, Anderson KC, Lin CP, Ghobrial IM (2007) Mechanisms of regulation of CXCR4/SDF-1 (CXCL12) dependent migration and homing in multiple myeloma. Blood 109:2708–2717PubMed Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, Spencer JA, Kimlinger T, Ghobrial JM, Jia X, Lu G, Timm M, Kumar A, Cote D, Veilleux I, Hedin KE, Roodman GD, Witzig TE, Kung AL, Hideshima T, Anderson KC, Lin CP, Ghobrial IM (2007) Mechanisms of regulation of CXCR4/SDF-1 (CXCL12) dependent migration and homing in multiple myeloma. Blood 109:2708–2717PubMed
73.
Zurück zum Zitat Giuliani N, Bonomini S, Romagnani P, Lazzaretti M, Morandi F, Colla S, Tagliaferri S, Lasagni L, Annunziato F, Crugnola M, Rizzoli V (2006) CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica 91(11):1489–1497PubMed Giuliani N, Bonomini S, Romagnani P, Lazzaretti M, Morandi F, Colla S, Tagliaferri S, Lasagni L, Annunziato F, Crugnola M, Rizzoli V (2006) CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica 91(11):1489–1497PubMed
74.
Zurück zum Zitat Arendt BK, Velazquez-Dones A, Tschumper RC, Howell KG, Ansell SM, Witzig TE, Jelinek DF (2002) Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells. Leukemia 16(10):2142–2147PubMedCrossRef Arendt BK, Velazquez-Dones A, Tschumper RC, Howell KG, Ansell SM, Witzig TE, Jelinek DF (2002) Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells. Leukemia 16(10):2142–2147PubMedCrossRef
75.
Zurück zum Zitat Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Gupta D, Richardson P, Munshi N, Anderson KC 2002) The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther 1(7):539–544PubMed Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Gupta D, Richardson P, Munshi N, Anderson KC 2002) The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther 1(7):539–544PubMed
76.
Zurück zum Zitat Parmo-Cabanas M, Bartolome RA, Wright N, Hidalgo A, Drager AM, Teixido J (2004) Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion. Exp Cell Res 294(2):571–580PubMedCrossRef Parmo-Cabanas M, Bartolome RA, Wright N, Hidalgo A, Drager AM, Teixido J (2004) Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion. Exp Cell Res 294(2):571–580PubMedCrossRef
77.
Zurück zum Zitat Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI, Anderson KC (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15:1950–1961PubMed Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI, Anderson KC (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15:1950–1961PubMed
78.
Zurück zum Zitat Vanderkerken K, Asosingh K, Braet F, Van Riet I, Van Camp B (1999) Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood 93(1):235–241PubMed Vanderkerken K, Asosingh K, Braet F, Van Riet I, Van Camp B (1999) Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood 93(1):235–241PubMed
79.
Zurück zum Zitat Menu E, Kooijman R, Van Valckenborgh E, Asosingh K, Bakkus M, Van Camp B, Vanderkerken K (2004) Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model. Br J Cancer 90(5):1076–1083PubMedCrossRef Menu E, Kooijman R, Van Valckenborgh E, Asosingh K, Bakkus M, Van Camp B, Vanderkerken K (2004) Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model. Br J Cancer 90(5):1076–1083PubMedCrossRef
80.
Zurück zum Zitat Qiang YW, Yao L, Tosato G, Rudikoff S (2004) Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells. Blood 103(1):301–308PubMedCrossRef Qiang YW, Yao L, Tosato G, Rudikoff S (2004) Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells. Blood 103(1):301–308PubMedCrossRef
81.
Zurück zum Zitat Qiang YW, Walsh K, Yao L, Kedei N, Blumberg PM, Rubin JS, Shaughnessy J Jr, Rudikoff S (2005) Wnts induce migration and invasion of myeloma plasma cells. Blood 106(5):1786–1793PubMedCrossRef Qiang YW, Walsh K, Yao L, Kedei N, Blumberg PM, Rubin JS, Shaughnessy J Jr, Rudikoff S (2005) Wnts induce migration and invasion of myeloma plasma cells. Blood 106(5):1786–1793PubMedCrossRef
82.
Zurück zum Zitat Van Valckenborgh E, Bakkus M, Munaut C, Noel A, St Pierre Y, Asosingh K, Van Riet I, Van Camp B, Vanderkerken K (2002) Upregulation of matrix metalloproteinase-9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells. Int J Cancer 101:512–518PubMedCrossRef Van Valckenborgh E, Bakkus M, Munaut C, Noel A, St Pierre Y, Asosingh K, Van Riet I, Van Camp B, Vanderkerken K (2002) Upregulation of matrix metalloproteinase-9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells. Int J Cancer 101:512–518PubMedCrossRef
83.
Zurück zum Zitat Vande Broek I, Asosingh K, Allegaert V, Leleu X, Facon T, Vanderkerken K, Van Camp B, Van Riet I (2004) Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia 18(5):976–982CrossRef Vande Broek I, Asosingh K, Allegaert V, Leleu X, Facon T, Vanderkerken K, Van Camp B, Van Riet I (2004) Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia 18(5):976–982CrossRef
84.
Zurück zum Zitat Barille S, Akhoundi C, Collette M, Mellerin MP, Rapp MJ, Harousseau JL, Bataille R, Amiot M (1997) Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 90:1649–1655PubMed Barille S, Akhoundi C, Collette M, Mellerin MP, Rapp MJ, Harousseau JL, Bataille R, Amiot M (1997) Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 90:1649–1655PubMed
85.
Zurück zum Zitat Asosingh K, Menu E, Van Valckenborgh E, Vande Broek I, Van Riet I, Van Camp B, Vanderkerken K (2002) Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma. Clin Exp Metastasis 19:583–591PubMedCrossRef Asosingh K, Menu E, Van Valckenborgh E, Vande Broek I, Van Riet I, Van Camp B, Vanderkerken K (2002) Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma. Clin Exp Metastasis 19:583–591PubMedCrossRef
86.
Zurück zum Zitat Westermarck J, Kahari VM (1999) Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13:781–792PubMed Westermarck J, Kahari VM (1999) Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13:781–792PubMed
87.
Zurück zum Zitat Nakamura T (1991) Structure and function of hepatocyte growth factor. Prog Growth Factor Res 3:67–85PubMedCrossRef Nakamura T (1991) Structure and function of hepatocyte growth factor. Prog Growth Factor Res 3:67–85PubMedCrossRef
88.
Zurück zum Zitat Jiang Y, Xu W, Lu J, He F, Yang X (2001) Invasiveness of hepatocellular carcinoma cell lines: contribution of hepatocyte growth factor, c-met, and transcription factor Ets-1. Biochem Biophys Res Commun 286:1123–1130PubMedCrossRef Jiang Y, Xu W, Lu J, He F, Yang X (2001) Invasiveness of hepatocellular carcinoma cell lines: contribution of hepatocyte growth factor, c-met, and transcription factor Ets-1. Biochem Biophys Res Commun 286:1123–1130PubMedCrossRef
89.
Zurück zum Zitat Monvoisin A, Bisson C, Si-Tayeb K, Balabaud C, Desmouliere A, Rosenbaum J (2002) Involvement of matrix metalloproteinase type-3 in hepatocyte growth factor-induced invasion of human hepatocellular carcinoma cells. Int J Cancer 97:157–162PubMedCrossRef Monvoisin A, Bisson C, Si-Tayeb K, Balabaud C, Desmouliere A, Rosenbaum J (2002) Involvement of matrix metalloproteinase type-3 in hepatocyte growth factor-induced invasion of human hepatocellular carcinoma cells. Int J Cancer 97:157–162PubMedCrossRef
90.
Zurück zum Zitat Borset M, Lien E, Espevik T, Helseth E, Waage A, Sundan A (1996) Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-Met in human myeloma cell lines. J Biol Chem 271:24655–24661PubMedCrossRef Borset M, Lien E, Espevik T, Helseth E, Waage A, Sundan A (1996) Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-Met in human myeloma cell lines. J Biol Chem 271:24655–24661PubMedCrossRef
91.
Zurück zum Zitat Derksen PW, de Gorter DJ, Meijer HP, Bende RJ, van Dijk M, Lokhorst HM, Bloem AC, Spaargaren M, Pals ST (2003) The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 17:764–774PubMedCrossRef Derksen PW, de Gorter DJ, Meijer HP, Bende RJ, van Dijk M, Lokhorst HM, Bloem AC, Spaargaren M, Pals ST (2003) The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 17:764–774PubMedCrossRef
92.
Zurück zum Zitat Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST (2002) Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 99:1405–1410PubMedCrossRef Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST (2002) Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 99:1405–1410PubMedCrossRef
93.
Zurück zum Zitat Vande Broek I, Leleu X, Schots R, Facon T, Vanderkerken K, Van Camp B, Van Riet I (2006) Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica 91(2):200–206PubMed Vande Broek I, Leleu X, Schots R, Facon T, Vanderkerken K, Van Camp B, Van Riet I (2006) Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica 91(2):200–206PubMed
94.
Zurück zum Zitat Uchida S, Shimada Y, Watanabe G, Li ZG, Hong T, Miyake M, Imamura M (1999) Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer 79:1168–1173PubMedCrossRef Uchida S, Shimada Y, Watanabe G, Li ZG, Hong T, Miyake M, Imamura M (1999) Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer 79:1168–1173PubMedCrossRef
95.
Zurück zum Zitat Drucker L, Tohami T, Tartakover-Matalon S, Zismanov V, Shapiro H, Radnay J, Lishner M (2006) Promoter hypermethylation of tetraspanin members contributes to their silencing in myeloma cell lines. Carcinogenesis 27:197–204PubMedCrossRef Drucker L, Tohami T, Tartakover-Matalon S, Zismanov V, Shapiro H, Radnay J, Lishner M (2006) Promoter hypermethylation of tetraspanin members contributes to their silencing in myeloma cell lines. Carcinogenesis 27:197–204PubMedCrossRef
96.
Zurück zum Zitat Tohami T, Drucker L, Shapiro H, Radnay J, Lishner M (2007) Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential. FASEB J 21(3):691–699PubMedCrossRef Tohami T, Drucker L, Shapiro H, Radnay J, Lishner M (2007) Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential. FASEB J 21(3):691–699PubMedCrossRef
Metadaten
Titel
Extravasation and homing mechanisms in multiple myeloma
verfasst von
Isabelle Vande Broek
Karin Vanderkerken
Benjamin Van Camp
Ivan Van Riet
Publikationsdatum
01.06.2008
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 4/2008
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-007-9108-4

Weitere Artikel der Ausgabe 4/2008

Clinical & Experimental Metastasis 4/2008 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.